ArticleFrontiers in oncology2025
Prediction of long-term survival in gastric cancer patients after immunotherapy based on CT-derived extracellular volume fraction.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gastric cancer remains a leading cause of cancer-related mortality. While immune checkpoint inhibitors (ICIs) have emerged as promising therapies, their efficacy is hindered by the lack of robust patient-centric biomarkers. CT-derived extracellular volume fraction (ECV) has emerged as a novel approach for non-invasive quantification of the extracellular matrix (ECM). This study assesses the predictive value of ECV, a non-invasive imaging biomarker, in gastric cancer patients receiving programmed death receptor-1 (PD-1) inhibitors. Methods: A retrospective study was conducted on 101 gastric adenocarcinoma patients (stage III: Results: Kaplan-Meier survival curves indicated that the ECV-higher group had shorter progression-free survival (PFS) ( Conclusion: CT-derived ECV may serve as an independent predictor of long-term survival in gastric cancer patients undergoing immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.